Predictors of antidepressant response to fluvoxamine obtained using the three-factor structures of the Montgomery and Åsberg Depression Rating Scale for major depressive disorders in Japanese patients

Psychiatry and Clinical Neurosciences

Volumn 62, Issue 3, 2008, Pages 301-306

  Higuchi, Hisashi ^a   Sato, Kazuhiro ^b   Yoshida, Keizo ^c   Takahashi, Hitoshi ^d   Kamata, Mitsuhiro ^e   Otani, Koichi ^e   Yamaguchi, Noboru ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Akita Kaiseikai Hospital   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^e YAMAGATA UNIVERSITY   (Japan)

Author keywords

Factor analysis; Fluvoxamine; Major depressive disorder; Montgomery and sberg Depression Rating Scale; Prediction of response

Indexed keywords

BROTIZOLAM; FLUVOXAMINE;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CORRELATION COEFFICIENT; FEMALE; HUMAN; INSOMNIA; JAPANESE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MELANCHOLIA; MENTAL PATIENT; MENTAL STRESS; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA AND VOMITING; PATIENT COMPLIANCE; PREDICTION AND FORECASTING; RANK SUM TEST; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSIVE DISORDER, MAJOR; FEMALE; FLUVOXAMINE; HUMANS; MALE; MIDDLE AGED; PERSONALITY INVENTORY; PROGNOSIS; PSYCHOMETRICS; REPRODUCIBILITY OF RESULTS;

EID: 45149083319     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2008.01797.x     Document Type: Article

References (17)

1. Gorman JM, Kent JM. SSRIs and SNRIs: Broad spectrum of efficacy beyond major depression. J. Clin. Psychiatry 1999 60 (Suppl. 4 33 38.
2. Sacchetti E. Fluvoxamine: Established evidence and emerging prospects in the short-term treatment of depression. In : Sacchetti E, Spano P (eds). Fluvoxamine: Established and Emerging Roles in Psychiatric Disorders. Excerpta Medica, Milano, 2000 27 47.
3. Morishita S, Arita S. Possible predictors of response to fluvoxamine for depression. Hum. Psychopharmacol. 2003 18 : 197 200.
4. Ueda N, Yoshimura R, Shinkai K et al. Plasma levels of catecholamine metabolites predict the response to sulpiride or fluvoxamine in major depression. Pharmacopsychiatry 2002 35 : 175 181.
5. Shinkai K, Yoshimura R, Ueda N et al. Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment. J. Clin. Psychopharmacol. 2004 24 : 11 17.
6. Yoshimura R, Nakamura J, Shinkai K et al. Clinical response to antidepressant treatment and 3-methoxy-4-hydroxyphenylglycol levels: Mini review. Prog. Neuropsychopharmacol. Biol. Pschiatry 2004 28 : 611 616.
7. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 1979 134 : 382 389.
8. Craighead WE, Evans DD. Factor analysis of the Montgomery-Åsberg Depression Rating Scale. Depression 1996 4 : 31 33.
9. Hammond MF. Rating depression severity in the elderly physically ill patient: Reliability and factor structure of the Hamilton and the Montgomery-Åsberg Depression Rating Scales. Int. J. Geriatr. Psychiatry 1998 13 : 257 261.
10. Parker RD, Flint EP, Bosworth HB et al. A three-factor analytic model of the MADRS in geriatric depression. Int. J. Geriatr. Psychiatry 2003 18 : 73 77.
11. Suzuki A, Aoshima T, Fukasawa T et al. A three-factor model of the MADRS in major depressive disorder. Depress. Anxiety 2005 21 : 95 97.
12. Muller MJ, Himmerich H, Kienzle B et al. Differentiating moderate and severe depression using the Montgomery-Åsberg Depression Rating Scale (MADRS). J. Affect. Disord. 2003 77 : 255 260.
13. Mendels J. The acute and long-term treatment of major depression. Int. Clin. Psychopharmacol. 1992 7 (Suppl. 2 21 29.
14. Fukuchi T, Kanemoto K. Differential effects of milnacipran and fluvoxamine, especially in patients with severe depression and agitated depression: A case-control study. Int. Clin. Psychopharmacol. 2002 17 : 53 58.
15. Sugawara Y, Higuchi H, Yoshida K et al. Response rate obtained using milnacipran depending on the severity of depression in the treatment of major depressive patients. Clin. Neuropharmacol. 2006 29 : 6 9.
16. Fabre L, Birkhimer LJ, Zaborny BA et al. Fluvoxamine versus imipramine and placebo: A double-blind comparison in depressed patients. Int. Clin. Psychopharmacol. 1996 11 : 119 127.
17. Zohar J, Keegstra H, Barrelet L. Fluvoxamine as effective as clomipramine against symptoms of severe depression: Results from a multicentre, double-blind study. Hum. Psychopharmacol. 2003 18 : 113 119.